A Predictive Modeling Approach to Support the Overfill Volume Definition of Liquid-in-Vial Drug Products

References

1. 1.↵
   1. Mathaes R.,
   2. Mahler H.-C.,
   3. Buettiker J.-P.,
   4. Roehl H.,
   5. Lam P.,
   6. Brown H.,
   7. Luemkemann J.,
   8. Adler M.,
   9. Huwyler J.,
   10. Streubel A.,
   11. Mohl S.

   The Pharmaceutical Vial Capping Process: Container Closure Systems, Capping Equipment, Regulatory Framework, and Seal Quality Tests. Eur. J. Pharm. Biopharm. 2016, 99, 54–64.

   OpenUrlPubMed
2. 2.↵
   1. Sacha G. A.,
   2. Saffell-Clemmer W.,
   3. Abram K.,
   4. Akers M. J.

   Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems. Pharm. Dev. Technol. 2010, 15 (1), 6–34.

   OpenUrlPubMed
3. 3.↵
   1. Hladik B.,
   2. Buscke F.,
   3. Frost R.,
   4. Rothhaar U.

   Comparative Leachable Study of Glass Vials to Demonstrate the Impact of Low Fill Volume. PDA J. Pharm. Sci. Technol. 2019, 73 (4), 345–355.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   U.S. Pharmacopeial Convention. General Chapter <1> Injections. In USP 43—NF 38, USP: Rockville, MD, 2020.
5. 5.↵
   U.S. Pharmacopeial Convention. General Chapter <1151> Pharmaceutical Dosage Forms. In USP 43—NF 38, USP: Rockville, MD, 2020.
6. 6.↵
   U.S. Pharmacopeial Convention. General Chapter <697> Container Content for Injections. In USP 43—NF 38, USP: Rockville, MD, 2020.
7. 7.↵
   Council of Europe, Test for Extractable Volume of Parenteral Preparations, Chapter 2.9.17. In European Pharmacopoeia (Ph. Eur.), 10th Edition, Council of Europe: Strasbourg, France, 2019.
8. 8.↵
   Ministry of Health Labour and Welfare of Japan, General Tests—6.05: Test for Extractable Volume of Parenteral Preparations. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2016.
9. 9.↵
   U.S. Food and Drug Administration, Guidance for Industry: Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services, Rockville, MD, 2015.
10. 10.↵
    1. Warne N. W.,
    2. Mahler H.-C.

    1. Dimitrova M. N.,
    2. Bee J. S.,
    3. Lu L.,
    4. Fernandez J. E.

    Development of Prefilled Syringe Combination Products for Biologics. In Challenges in Protein Product Development, 1st ed.; Warne N. W., Mahler H.-C., Eds.; AAPS Advances in the Pharmaceutical Sciences Series 38; Springer: Cham, Switzerland, 2018, pp 203–224.
11. 11.↵
    1. Sedita J.,
    2. Perrella S.,
    3. Morio M.,
    4. Berbari M.,
    5. Hsu J.-S.,
    6. Saxon E.,
    7. Jarrahian C.,
    8. Rein-Weston A.,
    9. Zehrung D.

    Cost of Goods Sold and Total Cost of Delivery for Oral and Parenteral Vaccine Packaging Formats. Vaccine 2018, 36 (12), 1700–1709.

    OpenUrl
12. 12.↵
    1. Gotham D.,
    2. Barber M. J.,
    3. Hill A. M.

    Estimation of Cost-Based Prices for Injectable Medicines in the WHO Essential Medicines List. BMJ Open 2019, 9 (9), e027780.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Hatswell A. J.,
    2. Porter J. K.

    Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes. Appl. Health Econ. Health Policy 2019, 17 (3), 391–397.

    OpenUrl
14. 14.↵
    1. Nema S.,
    2. Ludwig J. D.

    1. Manger W.

    Sterile Drug Product Process Validation. In Parenteral Medications, 4th ed.; Nema S., Ludwig J. D., Eds.; CRC Press: Boca Raton, FL, United States, 2019, pp 852–862.
15. 15.↵
    1. Mehta S. B.,
    2. Subramanian S.,
    3. Brown R.,
    4. D'Mello R.,
    5. Brisbane C.,
    6. Roy S.

    Use of a Predictive Regression Model for Estimating Hold-Up Volume for Biologic Drug Product Presentations. PDA J. Pharm. Sci. Technol. 2020, 74 (3), 290–300.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Warne N. W.,
    2. Mahler H.-C.

    1. Dixon D.,
    2. Gudinas A.

    Biotherapeutic Drug Product Manufacturing and Process Development. In Challenges in Protein Product Development, 1st ed.; Warne N. W., Mahler H.-C., Eds.; AAPS Advances in the Pharmaceutical Sciences Series 38; Springer: Cham, Switzerland, 2018, pp 353–383.
17. 17.↵
    1. Jameel F.,
    2. Hershenson S.

    1. Sethuraman A.,
    2. Pan X.,
    3. Mehta B.,
    4. Radhakrishnan V.

    Filling Process and Technologies for Liquid Biopharmaceuticals. In Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, 1st ed.; Jameel F., Hershenson S., Eds.; Wiley, 2010; pp 839–856.
18. 18.↵
    1. Joglekar A. M.

    Industrial Statistics: Practical Methods and Guidance for Improved Performance, 1st ed.; Wiley & Sons, Inc: Hoboken, NJ, 2010.
19. 19.↵
    1. Akers M. J.

    1. Kruszynski M. A.

    Sterile Product Filling, Stoppering and Sealing. In Sterile Drug Products: Formulation, Packaging, Manufacturing and Quality, 1st ed.; Akers M. J., Ed.; Drugs and the Pharmaceutical Sciences Book 208; Informa Healthcare: London, 2016; pp 278–293.
20. 20.↵
    1. Agalloco J. P.,
    2. Carleton F. J.

    1. Levine C. S.

    Validation of Packaging Operations. In Validation of Pharmaceutical Processes, 3rd ed.; Agalloco J. P., Carleton F. J., Eds.; CRC Press: New York, 2007, pp 429–442.
21. 21.↵
    International Organization for Standardization, ISO 8362-1: 2018: Injection Containers and Accessories — Part 1: Injection Vials Made of Glass Tubing. ISO: Geneva, 2018.
22. 22.↵
    International Council for Harmonisation. Harmonised Tripartite Guideline Q4B Annex 2 (R1): Test for Extractable Volume of Parenteral Preparations General Chapter. ICH: Geneva, 2010.
23. 23.↵
    1. Chatterjee S.,
    2. Simonoff S.

    Handbook of Regression Analysis, 1st ed.; Wiley Handbooks in Applied Statistics; Wiley: Hoboken, NJ, 2013.
24. 24.↵
    1. van der Schoot S. C.,
    2. Nuijen B.,
    3. Huitema A. D. R.,
    4. Beijnen J. H.

    Assessment of Performance of Manufacturing Procedures in a Unit for Production of Investigational Anticancer Agents, Using a Mixed Effects Analysis. Pharm. Res. 2007, 24 (3), 605–612.

    OpenUrlPubMed
25. 25.↵
    1. Montgomery D. C.

    Introduction to Statistical Quality Control, 6th ed.; Wiley & Sons, Inc: Hoboken, NJ, 2008.
26. 26.↵
    1. Jiang X.,
    2. Zhu C.,
    3. Ma Y.

    Density and Viscosity of Sorbitol/Maltitol in L-Ascorbic Acid Aqueous Solutions at T = (293.15 to 323.15) K. J. Mol. Liq. 2013, 188, 67–73.

    OpenUrl
27. 27.↵
    1. Zhu C.,
    2. Ma Y.,
    3. Zhou C.

    Densities and Viscosities of Sugar Alcohol Aqueous Solutions. J. Chem. Eng. Data 2010, 55 (9), 3882–3885.

    OpenUrlCrossRefWeb of Science
28. 28.↵
    1. Tomar D. S.,
    2. Li L.,
    3. Broulidakis M. P.,
    4. Luksha N. G.,
    5. Burns C. T.,
    6. Singh S. K.,
    7. Kumar S.

    In-Silico Prediction of Concentration-Dependent Viscosity Curves for Monoclonal Antibody Solutions. MAbs 2017, 9 (3), 476–489.

    OpenUrlCrossRef
29. 29.↵
    1. Besheer A.,
    2. Mahler H.-C.,
    3. Matter-Schwald A.,
    4. Barrenechea S. M.,
    5. Vogt M.,
    6. Chalus P.,
    7. Heymes P.,
    8. Pillow T.,
    9. Kirste A.,
    10. Favrod P.,
    11. Joerg S.,
    12. Mathaes R.

    Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs). Pharm. Res. 2020, 37 (4), 81.

    OpenUrl
30. 30.↵
    1. Woldeyes M. A.,
    2. Qi W.,
    3. Razinkov V. I.,
    4. Furst E. M.,
    5. Roberts C. J.

    How Well Do Low- and High-Concentration Protein Interactions Predict Solution Viscosities of Monoclonal Antibodies? J. Pharm. Sci. 2019, 108 (1), 142–154.

    OpenUrl
31. 31.↵
    1. Shieu W.,
    2. Lamar D.,
    3. Stauch O. B.,
    4. Maa Y.-F.

    Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms That Affect Precision of Low-Volume Fill by Peristaltic Pump. PDA J. Pharm. Sci. Technol. 2016, 70 (2), 143–156.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Nail S. L.,
    2. Akers M. J.

    Development and Manufacture of Protein Pharmaceuticals, 1st ed.; Pharmaceutical Biotechnology Vol. 14; Springer-Verlag: New York, 2012 (reprint).
33. 33.↵
    1. Rathore N.,
    2. Rajan R. S.

    Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations. Biotechnol. Prog. 2008, 24 (3), 504–514.

    OpenUrlPubMed
34. 34.↵
    1. Mathes J.,
    2. Friess W.

    Influence of pH and Ionic Strength on IgG Adsorption to Vials. Eur. J. Pharm. Biopharm. 2011, 78 (2), 239–247.

    OpenUrlPubMed
35. 35.↵
    1. Shi G. H.,
    2. Gopalrathnam G.,
    3. Shinkle S. L.,
    4. Dong X.,
    5. Hofer J. D.,
    6. Jensen E. C.,
    7. Rajagopalan N.

    Impact of Drug Formulation Variables on Silicone Oil Structure and Functionality of Prefilled Syringe System. PDA J. Pharm. Sci. Technol. 2018, 72 (1), 50–61.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Shieu W.,
    2. Torhan S. A.,
    3. Chan E.,
    4. Hubbard A.,
    5. Gikanga B.,
    6. Stauch O. B.,
    7. Maa Y.-F.

    Filling of High-Concentration Monoclonal Antibody Formulations into Pre-Filled Syringes: Filling Parameter Investigation and Optimization. PDA J. Pharm. Sci. Technol. 2014, 68 (2), 153–163.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Cambruzzi M.,
    2. Macfarlane P.

    Variation in Syringes and Needles Dead Space Compared to the International Organization for Standardization Standard 7886-1:2018. Vet. Anaesth. Analg. 2021, 48 (4), 532–536.

    OpenUrl
38. 38.↵
    1. Jameel F.,
    2. Hershenson S.,
    3. Khan M. A.,
    4. Martin-Moe S.

    1. Jameel F.,
    2. Undey C.,
    3. Kovach P. M.,
    4. Tanglertpaibul J.

    Application of QbD Elements in the Development and Scale-Up of Commercial Filling Process. In Quality by Design for Biopharmaceutical Drug Product Development, 1st ed.; Jameel F., Hershenson S., Khan M. A., Martin-Moe S., Eds.; AAPS Advances in the Pharmaceutical Sciences Series 18; Springer: New York, 2015; pp 265–302.
39. 39.↵
    1. Akers M. J.

    1. Akers M. J.

    Overview of Sterile Product Manufacturing. In Sterile Drug Products: Formulation, Packaging, Manufacturing and Quality, 1st ed.; Akers M. J., Ed.; Drugs and the Pharmaceutical Sciences Book 208; Informa Healthcare: London, 2016; pp 180–193.
40. 40.↵
    1. Jarrahian C.,
    2. Rein-Weston A.,
    3. Saxon G.,
    4. Creelman B.,
    5. Kachmarik G.,
    6. Anand A.,
    7. Zehrung D.

    Vial Usage, Device Dead Space, Vaccine Wastage, and Dose Accuracy of Intradermal Delivery Devices for Inactivated Poliovirus Vaccine (IPV). Vaccine 2017, 35 (14), 1789–1796.

    OpenUrlCrossRef